Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are highly effective at lowering hemoglobin A1c (HbA1c) and facilitating weight loss. Four agents in the GLP-1 RA class, albiglutide, liraglutide, dulaglutide, and semaglutide, also have cardioprotective effects. However, subcutaneous administration of these agents remains a major reason for their underutilization. A new coformulation of semaglutide with sodium N-[8-(2-hydroxybenzoyl) amino caprylate (SNAC) is the first oral GLP-1 RA reviewed by the U.S. Food and Drug Administration (FDA). The SNAC technology prevents destruction of semaglutide in the stomach and facilitates transcellular absorption through the gastric membrane enabling semaglutide to reach systemic circulation intact. The oral formulation of semaglutide was studied in the PIONEER trials, demonstrating similar efficacy to the presently available GLP-1 RAs with regard to HbA1c lowering and weight loss. Although the PIONEER 6 trial suggests positive effects on cardiovascular mortality with oral semaglutide, these benefits may not fully be appreciated until the completion of the SOUL trial.
['Bucheit|John D|JD|', 'Pamulapati|Lauren G|LG|', 'Carter|Nicole|N|', 'Malloy|Kevin|K|', 'Dixon|Dave L|DL|', 'Sisson|Evan M|EM|']
D000284:Administration, Oral D002210:Caprylates D002318:Cardiovascular Diseases D003924:Diabetes Mellitus, Type 2 D016503:Drug Delivery Systems D000067757:Glucagon-Like Peptide-1 Receptor D004763:Glucagon-Like Peptides D006801:Humans D007004:Hypoglycemic Agents D051436:Renal Insufficiency, Chronic
Semaglutide SNAC technology PIONEER trials Oral GLP-1 receptor agonists